Mercer Global Advisors
RXRX icon

Mercer Global Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Mercer Global Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$97.7K Buy
26,612
+5,263
+25% +$17.5K ﹤0.01% 3426
2026
Q1 		$65.5K Sell
21,349
-3,671
-15% -$14.2K ﹤0.01% 3094
2025
Q4 		$100K Buy
25,020
+8,935
+56% +$44.3K ﹤0.01% 2716
2025
Q3 		$78.5K Sell
16,085
-12,755
-44% -$67K ﹤0.01% 2556
2025
Q2 		$146K Sell
28,840
-3,640
-11% -$17.9K ﹤0.01% 2120
2025
Q1 		$172K Buy
32,480
+6,856
+27% +$50K ﹤0.01% 2000
2024
Q4 		$173K Sell
25,624
-3,310
-11% -$22.3K ﹤0.01% 1989
2024
Q3 		$179K Buy
+28,934
New +$207K ﹤0.01% 1825
2023
Q4 		– Sell
-14,259
Closed -$109K – 2079
2023
Q3 		$109K Buy
+14,259
New +$142K ﹤0.01% 1838

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mercer Global Advisors's RXRX Position: Q2 2026 in Review

Mercer Global Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 25% in Q2 2026, buying an estimated $17.5K and bringing the position to 26,612 shares worth $97.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3426.

Mercer Global Advisors first reported a position in RXRX in Q3 2023 and has held it in 9 quarters since. The position peaked at $179K in Q3 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Mercer Global Advisors held 26,612 shares of Recursion Pharmaceuticals worth $97.7K as of Q2 2026.
  • Mercer Global Advisors bought 5,263 Recursion Pharmaceuticals shares in Q2 2026, an estimated $17.5K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3426 holding.
  • Mercer Global Advisors first reported a position in Recursion Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
  • Mercer Global Advisors's Recursion Pharmaceuticals position peaked at $179K in Q3 2024.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.